Navigation Links
Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
Date:7/23/2010

An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute (LA BioMed) has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.

Researchers throughout the U.S. have begun administering the sickle cell treatment developed by investigators led by Yutaka Niihara, MD, MPH, at LA BioMed and licensed to Emmaus Medical, Inc. The patented drug treatment involves the oral administration of L-glutamine, which is the most common amino acid in the body. This is one of a very few experimental treatments for sickle cell disease to reach the Phase 3 clinical trial stage.

Sickle cell disease is an inherited disorder that causes red blood cells to become oxidized, sticky and sickle shaped instead of smooth, pliable and round. Sickle cell disease leads to anemia, organ damage, chronic and acute pain and a host of other problems.

"This is exciting news in the potential development of a novel new treatment for the millions of people who suffer from the painful effects of sickle cell disease," said Dr. Meyer. "We are proud of the dedication of Dr. Niihara and the team of researchers who first developed this treatment. They demonstrate the pioneering spirit that has kept LA BioMed at the forefront of translating discoveries into treatments that can transform lives."

Phase 3 clinical trials are large, randomized studies conducted at multiple sites to determine the safety and efficacy of a potential treatment. They are usually the last clinical trials conducted before the Food and Drug Administration gives its approval for a treatment to be made widely available to the patient population.

"As a physician I have seen firsthand the severe pain in patients with sickle cell disease, so I am very pleased we have reached this stage in our development of this potential treatment," said Dr. Niihara. "In the Phase 2 clinical trial, we observed an excellent safety profile and positive trends in decreasing the number of crises as well as reducing the frequency of hospitalizations in sickle cell disease patients. We look forward to the findings from the much larger group of research volunteers we will be seeking in the Phase 3 clinical trial."

In the Phase 3 clinical trial, researchers at 20 to 25 sites around the country will be seeking up to 225 research volunteers, age 5 years and older, with a diagnosis of sickle cell anemia or sickle beta O-thalassemia who have a history of at least two episodes of painful crisis during the past 12 months. The trial is a 53-week study requiring monthly visits to the research facility. It is funded by Emmaus Medical.


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert  

Related medicine news :

1. Sickle cell patients should be better monitored for constipation prevention
2. Stroke prevention study in children with sickle cell anemia, iron overload stopped early
3. NHLBI to hold workshop on health consequences of sickle cell trait
4. New study suggests sickle cell disease may affect brain function in adults
5. Sickle Cell Disease Tied to Cognitive Difficulties
6. Low blood oxygen may lead to heart defects in children with sickle cell disease
7. Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly
8. NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people
9. A new drug treatment to close the window on colon cancer
10. Improved treatment access requires end to portrayal of drug abusers as already dead
11. Writing checks that bounce: World continues to backtrack on HIV treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
(Date:7/7/2020)... ... July 07, 2020 , ... Great Point Partners (“GPP”) ... Board of Directors has appointed Rick Katz as Vice President of Business Development. ... best individual to assume this leadership role for the organization," said Adam Elberg, chairman ...
(Date:7/4/2020)... ... July 03, 2020 , ... Houston Life coach, Rashad Garrett, has thrown a ... the launch of his new app, Faith Of A Mustard Seed (FOAMS). , The ... mental health issues. In fact, a Federal Agency emergency helpline dedicated to helping people ...
(Date:7/2/2020)... ... July 02, 2020 , ... Dr. Christine Blaine has earned a ... medical offices located in Staten Island, Huntington and NYC, NY. Her former Manhattan ... medical suite at The Parlor NYC at 160 Madison Avenue. Blaine Plastic Surgery ...
(Date:7/2/2020)... ... July 02, 2020 , ... The ... offices for non-emergency work. In conjunction with the American Dental Association and Centers ... practices in mid-May. , Due to safety concerns, the announcement sparked hesitancy ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... development of psychedelics and analogues, announces its core executive team. The co-founders Drs. ... drug discovery, novel formulations, and as distinguished researchers within the cannabis industry. They ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... ... July 07, 2020 , ... With ... Navajo Nation residents, the 33 nonprofits who received the latest ISA Foundation ... round of funding, the foundation awarded grants totaling $838,527 to the U.S.-based 501(c)(3) ...
(Date:7/4/2020)... , ... July 03, 2020 , ... By Heidi Jean ... we’ve retreated into our homes for cover, Assuaged, Inc. is going full ... all over the globe this year to get their feet wet in marketing, social ...
(Date:7/2/2020)... ... July 02, 2020 , ... Realty ONE Group ... health series on its live agent Town Halls, furthering its commitment to its ... series includes special guests and Realty ONE Group leadership discussing social, mental, physical ...
Breaking Medicine Technology: